A phase III Equivalence Trial of PF 582 for the Treatment of Macular Degeneration (AMD)
Phase of Trial: Phase III
Latest Information Update: 09 May 2016
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- 09 May 2016 According to a Pfenex media release, the company is planning to initiate this trial in the second half of 2016.
- 16 Mar 2015 According to Pfenex media release, company is planning to initiate this trial in 2016.
- 12 Feb 2015 New trial record